TBXU ETF Analysis: Dividends, Returns AMEX:TBXU — TradingView

Key stats

TBXU provides 2x leveraged exposure to the top 5 US biotechnology companies. These five stocks are selected based on their market capitalization and are weighted equally. The fund primarily invests in financial instruments, such as swaps, futures, and ETFs tracking the index. Additionally, it may hold both index and non-index securities. Providing hyper-concentration in the energy sector, TBXU is not designed to be a long-term investment. Instead, it should be used as a short-term trading vehicle. The fund is a leveraged product with a 2x daily resetting factor and is likely to stray from the returns of the underlying index, especially over longer holding periods due to compounding. The fund may have a high portfolio turnover rate. The Index is rebalanced quarterly and reconstituted annually.

Classification

Returns

	1 month	3 months	Year to date	1 year	3 years	5 years
Price performance	—	—	—	—	—	—
NAV total return	—	—	—	—	—	—

Dividends

Dividend payout history

Assets under management (AUM)

Fund Flows

TBXU assets under management is ‪2.62 M‬ USD. It's risen 7.54% over the last month.

TBXU fund flows account for 0.00 USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.

No, TBXU doesn't pay dividends to its holders.

TBXU shares are issued by Rafferty Asset Management LLC under the brand Direxion. The ETF was launched on Oct 1, 2025, and its management style is Passive.

TBXU expense ratio is 0.97% meaning you'd have to pay 0.97% of your investment to help manage the fund.

TBXU follows the NYSE Biotechnology Top 5 Equal Weight Index - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

TBXU trades at a premium (0.01%) meaning the ETF is trading at a higher price than the calculated NAV.

Direxion Daily Biotech Top 5 Bull 2X ETF